Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The Company’s clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.